Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | PRGN-3006 |
Synonyms | |
Therapy Description |
PRGN-3006 is a cell-based therapy comprising autologous T-cells engineered to express membrane-bound IL15 and a chimeric antigen receptor (CAR) that recognizes CD33 as well as a kill switch, potentially resulting in increased anti-tumor response against CD33-expressing tumor cells (Blood (2019) 134 (Supplement_1): 2660). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PRGN-3006 | PRGN 3006|PRGN3006 | PRGN-3006 is a cell-based therapy comprising autologous T-cells engineered to express membrane-bound IL15 and a chimeric antigen receptor (CAR) that recognizes CD33 as well as a kill switch, potentially resulting in increased anti-tumor response against CD33-expressing tumor cells (Blood (2019) 134 (Supplement_1): 2660). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03927261 | Phase I | PRGN-3006 | PRGN-3006 Adoptive Cellular Therapy Relapsed or Refractory AML or High Risk MDS | Active, not recruiting | USA | 0 |